Cancer Genetics, Inc. Launches Webinar Series to Drive Awareness and Adoption of Its Proprietary DNA-Based Cervical Cancer Diagnostic Test

RUTHERFORD, N.J., Jan. 29, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, is launching a webinar series to inform clinicians and pathologists of the value of its proprietary DNA-based test for cervical cancer, FHACT™, which is processed in the Company's CLIA certified, clinical laboratory. The webinar series will begin on Friday, January 31, at 9:30 a.m. ET and will be available again on Thursday, February 6, at 9:30 a.m. ET.

CGI's webinar series, "An introduction to FHACT™: the FISH-based HPV-Associated Cancer Test," was designed by Jane Houldsworth, PhD, Vice President of R&D at CGI, to better inform clinicians and pathologists about the value of using FHACT™ to help in triaging women with low grade cytological abnormalities prior to colposcopy.

Dr. Houldsworth led the research study of FHACT™ at CGI in collaboration with the National Cancer Institute (NCI). Data from the study was published in the July 2013 issue of Gynecologic Oncology ( where the genetic regions assessed in FHACT™ were found to be associated with severity of cervical lesions.

"About 2 million women are referred each year in the U.S. to undergo colposcopy, based on abnormal cytology and HPV testing, and of these significantly less than half require additional medical follow-up for diagnosed precancerous and cancerous lesions. Thus, there is a need to identify with greater efficiency women who are at risk to have such medically actionable lesions prior to referral for colposcopy. FHACT™ has the potential to reduce the health-care burden associated with cervical cancer and requires no further sample from the patient," commented Dr. Houldsworth. "The potential of FHACT™ to provide more accurate and earlier detection of HPV-associated cancers and pre-cancers can save valuable time in the testing process, while creating substantial cost savings for the healthcare system."

Although approximately 90% of HPV infections will be cleared within 2 years, a minority of precancerous lesions will progress to a higher-grade lesion. Women diagnosed with LSIL (low-grade squamous intraepithelial lesions) have a marginally higher risk of progression, and current high-risk HPV testing does not provide additional benefit in risk assessment for cancer. It is in these clinical settings where the integration of additional genetic biomarkers in the triage process is needed to limit unnecessary colposcopies and excisional procedures and to identify those women with lesions that are at risk of progressing to a higher grade cervical cancer.

CGI's non-invasive FHACT™ test provides genomic information directly from leftover liquid cytology and does not require additional office visits. By using a unique combination of four genetic biomarkers, the FHACT™ test increases the sensitivity of detection of cells that show genomic abnormalities.

To register for the webinar series, please visit:

The webinar series will be hosted by CGI's Associate Product Manager, Alexandra Arndt, BS, CG (ASCP). Registered attendees of the live webinars can participate in Q&A sessions with Ms. Arndt. For those unable to attend the live events, the webinar series will be available for on demand viewing.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended September 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 jon@redchip.comSource:Cancer Genetics